Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
B. Robinson (Perth, Australia). Keynote lecture: Introduction: Treatment options and tumour biology of malignant pleural mesothelioma. Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma

Member's Comments

No comment yet.

Related content which might interest you: Immunotherapy for malignant pleural mesothelioma: ready for clinical practice? Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies? Year: 2016 Multimodal management of malignant pleural mesothelioma: where are we today? Source: Eur Respir J 2014; 44: 754-764 Year: 2014 Malignant pleural mesothelioma: new treatments, new hopes? Source: Eur Respir J , 49 (3) 1700319; DOI: 10.1183/13993003.00319-2017 Year: 2017 Treatment of malignant pleural mesothelioma: dilemmas Source: Eur Respir J 2005; 26: Suppl. 49, 73s Year: 2005 Malignant pleural mesothelioma: Current status and future projections in Turkey Source: International Congress 2015 – Mediastinal tumors, malignant pleural mesothelioma and other rare tumors Year: 2015 Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment Source: Eur Respir Rev 2016; 25: 472-486 Year: 2016 Malignant mesothelioma vs metastatic carcinoma of pleura: Do pathology and radiology agree? Source: Annual Congress 2013 –Morphologic imaging Year: 2013 Malignant pleural mesothelioma: our multimodality approach Source: Eur Respir J 2002; 20: Suppl. 38, 40s Year: 2002 Role of tumor derived versican in experimental malignant pleural mesothelioma Source: International Congress 2016 – Mesothelioma and pleural disease: from the bench to the bedside Year: 2016 Update on biology and management of mesothelioma Source: Eur Respir Rev, 30 (159) 200226; 10.1183/16000617.0226-2020 Year: 2021 Intrapleural photodynamic therapy for malignant pleural mesothelioma: A new dosimetry approach Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 LATE-BREAKING ABSTRACT: Host-environmental IL-1ß drives mutant KRAS-IKKa addiction in malignant pleural effusion Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management Year: 2015 Diagnosis of malignant pleural mesothelioma: the clinician and pathologist points of view Source: Annual Congress 2009 - Malignant pleural mesothelioma guidelines Year: 2009 Contemporary management of malignant mesothelioma Source: Annual Congress 2004 - PG20 - State-of-the art in management of pleural diseases Year: 2004 Solitary fibrous tumour of the pleural: Two malignant cases Source: International Congress 2015 – Mediastinal tumors, malignant pleural mesothelioma and other rare tumors Year: 2015 Phenotyping malignant pleural effusions: why? Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs Year: 2017 Malignant mesothelioma diagnosed at medical thoracoscopy – A service review Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases Year: 2013